Trial Profile
Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-modifying Treatments for Myasthenia Gravis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Azathioprine (Primary) ; Mycophenolate mofetil (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROMISE-MG
- 02 Feb 2021 Status changed from recruiting to completed.
- 11 Dec 2020 Planned End Date changed from 1 Nov 2020 to 31 Jan 2021.
- 11 Dec 2020 Planned primary completion date changed from 1 Nov 2020 to 31 Jan 2021.